1. Startpage
  2. Johannes Gutenberg-Universität Mainz
  3. DFG-491381577-H
Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-9513
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBoedecker-Lips, Simone-
dc.contributor.authorJudel, Andreas-
dc.contributor.authorHoltz, Stefan-
dc.contributor.authorMayer, Magnus-
dc.contributor.authorKlimpke, Pascal-
dc.contributor.authorKraus, Daniel-
dc.contributor.authorSchreiner, Thomas-
dc.contributor.authorGerstmayer, Bernhard-
dc.contributor.authorEulitz, Klaus-
dc.contributor.authorMayer, Magnus Christopher-
dc.contributor.authorWeinmann-Menke, Julia-
dc.date.accessioned2023-09-29T08:15:05Z-
dc.date.available2023-09-29T08:15:05Z-
dc.date.issued2023-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/9531-
dc.description.abstractBackground Gene therapies based on adeno-associated viruses (AAV) are a therapeutic option to successfully treat monogenetic diseases. However, the influence of pre-existing immunity to AAV can compromise the application of AAV gene therapy, most notably by the presence of neutralizing antibodies (NAb) to AAV. Methods In the following study, we investigated to what extent the treatment by immunoadsorption (IA) would reduce the levels of human anti-AAV antibodies to AAV2 and AAV5. To that end, we screened blood sera from 40 patients receiving IA treatment because of underlying autoimmune disease or transplant rejection, with detectable AAV-antibodies in 23 patients (22 by NAb detection, and 1 additionally by anti-AAV5 ELISA analysis). Results Our results show that IA efficiently depleted anti-AAV2 NAb with a mean reduction of 3.92 ± 1.09 log2 titer steps (93.4%) after three to five single IA treatments, 45% of seropositive subjects had an anti-AAV2 titer below the threshold titer of 1:5 after the IA treatment series. Anti-AAV5 NAb were reduced to below the threshold titer of 1:5 in all but one of five seropositive subjects. Analysis of total anti-AAV5 antibodies by ELISA demonstrated an anti-AAV5 antibody reduction over the IA treatment series of 2.67 ± 1.16 log2 titer steps (84.3%). Conclusion In summary, IA may represent a safe strategy to precondition patients with pre-existing anti-AAV antibodies to make this population eligible for an effective AAV-based gene therapy.en_GB
dc.description.sponsorshipDeutsche Forschungsgemeinschaft (DFG)|491381577|Open-Access-Publikationskosten 2022–2024 Universität Mainz - Universitätsmedizin-
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleEfficient removal of antibodies to adeno-associated viruses by immunoadsorptionen_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-9513-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleJournal of clinical apheresisde
jgu.journal.volumeVersion of Record (VoR)de
jgu.publisher.year2023-
jgu.publisher.nameWiley Intersciencede
jgu.publisher.placeNew York, NYde
jgu.publisher.issn1098-1101de
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
jgu.publisher.doi10.1002/jca.22069de
jgu.organisation.rorhttps://ror.org/023b0x485-
Appears in collections:DFG-491381577-H

Files in This Item:
  File Description SizeFormat
Thumbnail
efficient_removal_of_antibodi-20230901144023757.pdf1.56 MBAdobe PDFView/Open
Show simple item record